^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Empliciti (elotuzumab)

    i
    Other names: BMS-901608, HuLuc63, PDL063, BMS901608, BMS 901608, HuLuc-63, PDL 036, PDL-063
    Company:
    AbbVie, BMS
    Drug class:
    CS-1 inhibitor
    Related drugs:
    7d
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Dec 2028
    Trial completion date
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    14d
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2029 --> Oct 2028
    Enrollment open • Trial primary completion date
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    28d
    Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Abdullah Khan | Recruiting --> Active, not recruiting | N=27 --> 12
    Enrollment closed • Enrollment change • IO biomarker
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon)
    |
    Empliciti (elotuzumab) • Hemady (dexamethasone tablets) • mezigdomide (CC-92480) • dexamethasone injection
    28d
    Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf)
    1m
    STOMP: Selinexor and Backbone Treatments of Multiple Myeloma Patients (clinicaltrials.gov)
    P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • carfilzomib • pomalidomide • Empliciti (elotuzumab) • Blenrep (belantamab mafodotin-blmf) • mezigdomide (CC-92480)
    1m
    Elotuzumab enhances the anti-tumor activity of Vγ9Vδ2 T cells against Primary Effusion Lymphoma. (PubMed, Eur J Pharmacol)
    Elo treatment significantly increased γδ T cell cytotoxicity and degranulation, and these effects were prevented by Fc receptor blockade or by Fc-deficient Elo, indicating an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Our findings demonstrate for the first time that Elo directly boosts γδ T cell anti-tumor activity against PEL, offering novel preclinical evidence for combining Elo with γδ T cell therapy as a potential treatment strategy for this intractable lymphoma.
    Journal
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)
    1m
    MonumenTAL-6: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (clinicaltrials.gov)
    P3, N=795, Recruiting, Janssen Research & Development, LLC | N=468 --> 795
    Enrollment change
    |
    lenalidomide • bortezomib • pomalidomide • Empliciti (elotuzumab) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv) • dexamethasone injection
    1m
    CEVOLUTION: Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma (clinicaltrials.gov)
    P3, N=380, Not yet recruiting, Hoffmann-La Roche
    New P3 trial
    |
    carfilzomib • dexamethasone • pomalidomide • Empliciti (elotuzumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • cevostamab (RG6160)
    1m
    SWOG-1211: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=142, Completed, SWOG Cancer Research Network | Active, not recruiting --> Completed
    Trial completion
    |
    SKY92 Test
    |
    lenalidomide • bortezomib • Empliciti (elotuzumab) • dexamethasone injection
    2ms
    CA204-185: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab (clinicaltrials.gov)
    P2, N=67, Completed, Bristol-Myers Squibb | Trial completion date: Nov 2025 --> Feb 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • lenalidomide • bortezomib • dexamethasone • pomalidomide • Empliciti (elotuzumab)
    2ms
    IMPEDE: Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting | N=53 --> 28 | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    pomalidomide • Sarclisa (isatuximab-irfc) • Empliciti (elotuzumab)
    3ms
    Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis. (PubMed, Ann Med)
    Elotuzumab in MM appears safe but with a specific adverse events pattern : lower neutropenia, but higher respiratory, gastrointestinal, metabolic, and infectious events. Differences may be influenced by longer treatment and corticosteroid use; therefore, interpretation of outcomes such as hyperglycemia and cataracts requires particular caution.
    Retrospective data • Journal • Adverse events
    |
    SLAMF7 (SLAM Family Member 7)
    |
    Empliciti (elotuzumab)